What question did this study set out to answer?

To determine whether concurrent genetic alterations influence clinical outcomes, treatment response, and survival in patients with advanced EGFR-mutant NSCLC receiving first-line TKIs.

May 17, 2021CancersOpen Access

Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations

View Full Paper

Ask AI

Bookmark

To determine whether concurrent genetic alterations influence clinical outcomes, treatment response, and survival in patients with advanced EGFR-mutant NSCLC receiving first-line TKIs.
Retrospectively evaluated N=106 consecutive patients with advanced EGFR-positive NSCLC receiving first-line tyrosine kinase inhibitor therapy.
Performed next-generation sequencing targeting 22 cancer-related genes and assessed PD-L1 expression on baseline diagnostic tissue samples.
Concomitant pathogenic mutations occurred in 59 of 106 specimens, with no significant differences between patients without vs. with co-alterations for mOS (22.8 vs. 29.5 months; p = 0.088), mPFS (10.9 vs. 11.2 months; p = 0.415), or ORR (55.9% vs. 68.1%; p = 0.202).
Presence of co-alterations correlated significantly with younger age (p = 0.018) and baseline lymph node metastases (p = 0.032), but did not differ by EGFR mutation subtype, TKI generation, or PD-L1 expression level.
Patients lacking concomitant alterations had a significantly higher incidence of bone progression compared to those with co-alterations (26.5% vs. 3.3%, p = 0.011).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort study finds that co-mutations do not impact survival or response to first-line TKIs in advanced EGFR-positive NSCLC, suggesting limited predictive value for initial therapy.

Cite This Study

Bironzo et al. (2021) studied this question.

synapsesocial.com/papers/6aa2e700d081bdd435a7330a https://doi.org/10.3390/cancers13102425

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study finds that co-mutations do not impact survival or response to first-line TKIs in advanced EGFR-positive NSCLC, suggesting limited predictive value for initial therapy.

Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations

Key Points

Discussion

Implication

Cite This Study

Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider